BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.76 USD
-0.09 (-10.05%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $0.77 +0.01 (0.71%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 161 - 180 ( 205 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Strong Preclinical Support and Prepping for Important Clinical Data Soon
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Healthcare - End of 2014 Biotech Highlights: Partnering Watch & Major Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BL-8040 Stem Cell Mobilization Study Gets Going; Data Soon; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BL-7010 IP Coverage Expands; Additional Milestones Approaching
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2Q14 Results; After Quiet 2Q, Several Catalysts on Horizon; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
7010 Results Point Toward Medical Device Classification; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
''7010 Results Point Toward Medical Device Classification; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
We are reinstating coverage with a Buy rating and an $8 price target.
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Consideration Expands for BL-8040, A Potential Portfolio Gem
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.